New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28—Oct 2) and appearing in The Lancet shows that treatment with the new triple agonist therapy retatrutide results in substantial weight loss and improvements in blood sugar control in people living with obesity or overweight and type 2 diabetes—a population that has generally experienced less weight loss with obesity medications than people without diabetes.
❓ Unknown
Triple Agonist Drug Retatrutide Shows Promise for Weight Loss in Diabetic Patients
Just now
October 1, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
New research presented at the EASD Annual Meeting reveals that the triple agonist drug retatrutide significantly aids weight loss and blood sugar control in diabetic patients. This finding is crucial for managing obesity-related health issues, particularly in populations like Iran where diabetes is prevalent. The implications for healthcare strategies in Iran could be substantial.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
6 min ago •
Slight Increase in Gold Prices in Global Market
9 min ago •
Resignation of Teachers or Social Media Hype? / Announce Accurate Resignation Statistics
10 min ago •
Successful Implementation of the National Housing Movement Plan in Sistan and Baluchestan
14 min ago •
Who is Responsible for the Cost of Water Meter Damage and Replacement?
14 min ago •